Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05907980 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by Chugai Pharmaceutical.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 219
- Enrollment target
- 4
- Study locations
NCT05907980 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by Chugai Pharmaceutical. The registered enrollment target is 219 participants, roughly in line with the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target. The trial reports 4 study locations across 4 states.
The verdict
NCT05907980, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by Chugai Pharmaceutical.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 219 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid tumors. The study will consist of three parts: a dose-escalation part, a biopsy part (the part to evaluate biomarkers), and an expansion part.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG ROSE12
Study Locations (4)
Texas
- MD Anderson Cancer Center - Houston
Virginia
- NEXT Oncology - Fairfax
Chiba
- National Cancer Center Hospital East - Kashiwa-shi
Tokyo
- National Cancer Center Hospital - Chuo-ku
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2023-05-24 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05907980
The ClinicalTrials.gov registry entry for NCT05907980 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 219 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target. The listed sponsor is Chugai Pharmaceutical, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.
NCT05907980 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Texas, Virginia, Chiba.
Frequently Asked Questions
What is clinical trial NCT05907980 about?
NCT05907980 is a clinical study titled "A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors". This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid tumors. The study will consist of three parts: a dose-escalation part,...
What is the current status of trial NCT05907980?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 219 participants. The study started on 2023-05-24. Estimated completion is 2026-12-31.
What conditions does trial NCT05907980 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT05907980?
The interventions under investigation include: Atezolizumab (DRUG), ROSE12 (DRUG).
Who is sponsoring clinical trial NCT05907980?
This trial is sponsored by Chugai Pharmaceutical, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05907980 being conducted?
This trial has 4 study locations across Texas, Virginia, Chiba, Tokyo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.